New antiplatelet agents

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 9, 2009, Pages 584-587

  Angiolillo, Dominick ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BRILINTA; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2C19; E 5555; EFFIENT; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; METOPROLOL; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; SCH 530348; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AFRICAN AMERICAN; AGE; ARTICLE; ASIAN; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PATIENT COMPLIANCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRESCRIPTION; RASH; RISK BENEFIT ANALYSIS; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANIMALS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; RECEPTORS, PURINERGIC P2;

EID: 70349675752     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624-9.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
3. Steinhubl SR, Berger PB, Mann JT for the CREDO Investigators. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. A Randomized Controlled Trial. JAMA. 2002;288:2411-2420.
4. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
5. Chen ZM, Jiang LX, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Lancet. 2005;366:1607-1621.
6. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(3 Suppl):27A-34A.
7. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
8. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009.
9. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919-928.